Blood Test Study for Detecting Colorectal Cancer
Studies a blood-based test to detect colorectal cancer in adults aged 45 to 75.
Plain-language title generated from the registry record
Registry title: Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD
Key facts
- Where
- Mendoza, ArgentinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 75 years old?
Source: NCT07148297, who can take part
Where in Argentina
- EpiliquidMendoza, ArgentinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Epiliquid Holding, Inc
- Trial code
- NCT07148297
- Record updated
- 29 August 2025
- Original description
CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methylation biomarkers for different cancer types. In this study, colorectal cancer-specific biomarkers will be evaluated in blood and tissue samples using delta-HLD technology, which enables sensitive and multiplexed detection through PCR. Study results will support the validation of Epiliquid's integrated platform as a minimally invasive and accessible diagnostic solution for colorectal cancer.Read full original descriptionShow less
Proof-of-concept Case-control Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CASCADE)
CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methylation biomarkers for different cancer types. In this study, colorectal cancer-specific biomarkers will be evaluated in blood and tissue samples using delta-HLD technology, which enables sensitive and multiplexed detection through PCR. Study results will support the validation of Epiliquid's integrated platform as a minimally invasive and accessible diagnostic solution for colorectal cancer.
Inclusion: Candidate for colonoscopy or colorectal surgery; Willing and able to provide informed consent; Able to provide blood and/or tissue sample before treatment or resection.
Exclusion: Prior history of colorectal cancer; Recent chemotherapy or immunosuppressive treatment; Inflammatory bowel disease; Known hereditary cancer syndromes (e.g., Lynch, FAP); Other active malignancies.